GENESIS IBRC INDIA : Q4 2024 Financial Quarterly Report

The financial outlook for the company under BSE code 514336 reveals a significant five-year profit of 0 percents. This marks a notable increase to 0 percents over the last three years, indicating a strong upward trend in the company's financial health during this period. However, it's important to note that recent challenges have impacted the company's performance, leading to a trailing twelve-month loss of -2636 percents. This sharp decline in profitability is particularly concerning, as the company has also reported no sales across any analyzed timeframe, suggesting a highly unconventional and perhaps risky operational approach. The company's stock prices mirror this financial volatility, with the stock trading at 14 percents over the past five years but experiencing a dramatic drop to 41 percents within the last year. Over a decade, the stock price was at 0 percents, reflecting long-term concerns regarding the company's stability and future outlook. Such performance poses questions about the sustainability of the business and whether it can rebound from these recent setbacks.

Currently valued at ₹20.6 crore, the company's stock price stands at ₹15.8. Over the years, it has seen significant fluctuations, with its price ranging from ₹15.8 / 9.73, a reflection of its sensitivity to market conditions and investor sentiment. The stock's Price-to-Earnings (P/E) ratio, currently at , suggests that it is highly valued in comparison to its earnings, possibly indicating strong future growth expectations or a high level of investor confidence. The book value per share is ₹7.39, which represents the net asset value of the company per share. The dividend yield of 0.00% provides some return to investors, though it may not be the primary attraction for those investing in the stock. The company's Return on Capital Employed (ROCE) is %, pointing to efficient use of its capital base to generate profits. The Return on Equity (ROE), at %, highlights the profitability for shareholders. The company's financial health is further underscored by its very low debt-to-equity ratio of 0.15, signaling conservative financial management. However, the net cash flow is negative at ₹0.02 crore, indicating possible liquidity concerns or heavy investment. The Piotroski score of 2.00 provides a snapshot of its financial stability, while the Graham Number, estimated at ₹, offers an intrinsic value benchmark. With a Price-to-Book (P/B) ratio of 2.14, the stock seems to be trading at a premium relative to its book value, which could signal strong market expectations or overvaluation risks.